BMC Cancer

Table 4 Mean scores of hospital anxiety and depression score (HADS) during the study period

From: Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial

HADS (Anxiety)						HADS (Depression)
		Number	mean ± standard division	SE	P-value	mean ± standard division	SE	P-value
Baseline	Placebo	14	8.5 ± 2.8	0.76	0.7	7 ± 3.1	0.83	0.77
Baseline	Bupropion	13	9 ± 3	0.8		5.7 ± 2.5	0.7
End of 2_nd week	Placebo	14	8.2 ± 2.5	0.68	0.8	6.4 ± 2.9	0.79	0.13
End of 2_nd week	Bupropion	13	8 ± 2.7	0.77		4.7 ± 2.4	0.69
End of 6_th week	Placebo	14	6.5 ± 0.6	0.7	0.22	4.7 ± 2.5	0.68	0.03
End of 6_th week	Bupropion	13	5.3 ± 1.8	0.5		2.8 ± 1.7	0.47

HADS_A Hospital Anxiety and Depression Scale (Anxiety).
HADSD Hospital Anxiety and Depression Scale (Depression).

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com